Share Price and Basic Stock Data
Last Updated: October 28, 2025, 3:18 am
| PEG Ratio | -9.90 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Laurus Labs Ltd operates in the pharmaceuticals sector, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs) and formulations. As of Mar 2025, the company reported sales of ₹5,217 Cr, a decrease from ₹5,773 Cr in Mar 2023, reflecting a challenging market environment. The trailing twelve months (TTM) revenue was reported at ₹5,533 Cr, indicating a slight decline from the previous fiscal year. Quarterly sales figures showed a notable dip in Jun 2023 to ₹1,108 Cr, but a recovery was seen in Mar 2025, which rose to ₹1,650 Cr. This volatility in revenue can be attributed to various operational challenges, including regulatory hurdles and market competition. Despite these challenges, the company has maintained a strong market capitalization of ₹49,874 Cr, reflecting investor interest and confidence in its long-term potential.
Profitability and Efficiency Metrics
The profitability of Laurus Labs is characterized by its operating profit margin (OPM), which stood at 18% for Mar 2025, a decline from 26% in Mar 2023. The company reported a net profit of ₹380 Cr for Mar 2025, down from ₹760 Cr in Mar 2023. The return on equity (ROE) was recorded at 7.75%, while the return on capital employed (ROCE) was at 9.47%, indicating moderate efficiency in generating returns on shareholder investments. Operating profit for the latest fiscal year was ₹944 Cr, reflecting a decrease from ₹1,482 Cr the previous year. The interest coverage ratio (ICR) was a healthy 5.55x, suggesting that the company can comfortably meet its interest obligations. However, the decline in profitability metrics raises concerns about operational efficiency and cost management amidst increasing expenses, which totaled ₹4,273 Cr for Mar 2025.
Balance Sheet Strength and Financial Ratios
Laurus Labs maintains a robust balance sheet, with total assets amounting to ₹8,587 Cr and total liabilities at ₹8,587 Cr as of Mar 2025. The company reported reserves of ₹4,456 Cr, which provides a cushion against market fluctuations. Borrowings stood at ₹2,380 Cr, indicating a manageable debt level with a long-term debt-to-equity ratio of 0.14, reflecting conservative leverage. The price-to-book value (P/BV) ratio was recorded at 7.40x, suggesting that the stock may be trading at a premium compared to its book value, which stood at ₹82.99 per share. Current and quick ratios were at 1.22x and 0.67x, respectively, indicating adequate liquidity to meet short-term obligations. However, the cash conversion cycle (CCC) of 262 days signals potential inefficiencies in inventory and receivables management, which could affect cash flow.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Laurus Labs reveals a balanced investor base, with promoters holding 27.60% of the shares, while foreign institutional investors (FIIs) accounted for 25.70% and domestic institutional investors (DIIs) held 11.94%. Public shareholders comprised 34.78%, with a total of 2,80,223 shareholders as of Jun 2025. This diversified ownership structure indicates a healthy level of investor confidence, although the decline in public ownership from 41.38% in Dec 2022 to 34.78% in Jun 2025 raises questions about retail investor sentiment. The increase in FII holdings from 22.67% in Sep 2022 to 25.70% in Jun 2025 suggests growing confidence among institutional investors. The company’s consistent dividend payout ratio of 12.03% for Mar 2025 reflects its commitment to returning value to shareholders, despite recent fluctuations in profitability.
Outlook, Risks, and Final Insight
Looking ahead, Laurus Labs faces both opportunities and challenges. The company’s strong market position and diversification into high-growth segments such as formulation services provide a solid foundation for future growth. However, risks include regulatory pressures, market competition, and potential supply chain disruptions. The recent decline in profitability metrics may signal underlying operational inefficiencies that need to be addressed. Additionally, the high P/BV ratio could indicate that the stock is overvalued, raising concerns for potential investors. If Laurus Labs can effectively manage its costs and improve operational efficiencies, it may regain its growth trajectory. Conversely, failure to address these issues could lead to further declines in profitability and investor confidence. Overall, the company’s long-term prospects appear promising, but vigilance is required to navigate the inherent risks in the pharmaceuticals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Laurus Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 115 | 247/84.3 | 32.9 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.81 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,091 Cr. | 470 | 479/192 | 114 | 22.8 | 0.14 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.5 Cr. | 49.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.7 Cr. | 21.0 | 29.1/17.0 | 32.0 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,817.92 Cr | 1,181.71 | 50.34 | 194.36 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,495 | 1,498 | 1,501 | 1,279 | 1,108 | 1,158 | 1,132 | 1,415 | 1,117 | 1,185 | 1,265 | 1,650 | 1,433 |
| Expenses | 1,077 | 1,072 | 1,116 | 1,027 | 980 | 978 | 962 | 1,143 | 956 | 1,003 | 1,059 | 1,255 | 1,105 |
| Operating Profit | 418 | 426 | 385 | 252 | 128 | 181 | 170 | 271 | 161 | 182 | 206 | 395 | 327 |
| OPM % | 28% | 28% | 26% | 20% | 12% | 16% | 15% | 19% | 14% | 15% | 16% | 24% | 23% |
| Other Income | 3 | 4 | 3 | 6 | 7 | 6 | 11 | 24 | 9 | 12 | 7 | 72 | 22 |
| Interest | 28 | 38 | 39 | 41 | 33 | 38 | 38 | 42 | 41 | 45 | 48 | 49 | 44 |
| Depreciation | 66 | 76 | 78 | 81 | 84 | 85 | 87 | 89 | 91 | 91 | 89 | 88 | 94 |
| Profit before tax | 328 | 317 | 270 | 137 | 17 | 63 | 57 | 164 | 39 | 58 | 77 | 330 | 211 |
| Tax % | 29% | 28% | 26% | 25% | 24% | 26% | 25% | 26% | 26% | 27% | 25% | 24% | 25% |
| Net Profit | 232 | 227 | 199 | 102 | 13 | 47 | 43 | 121 | 29 | 42 | 57 | 252 | 158 |
| EPS in Rs | 4.31 | 4.23 | 3.70 | 1.90 | 0.24 | 0.87 | 0.79 | 2.25 | 0.53 | 0.79 | 1.06 | 4.67 | 2.93 |
Last Updated: August 1, 2025, 6:00 pm
Below is a detailed analysis of the quarterly data for Laurus Labs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,433.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,650.00 Cr. (Mar 2025) to 1,433.00 Cr., marking a decrease of 217.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,105.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,255.00 Cr. (Mar 2025) to 1,105.00 Cr., marking a decrease of 150.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 327.00 Cr.. The value appears to be declining and may need further review. It has decreased from 395.00 Cr. (Mar 2025) to 327.00 Cr., marking a decrease of 68.00 Cr..
- For OPM %, as of Jun 2025, the value is 23.00%. The value appears to be declining and may need further review. It has decreased from 24.00% (Mar 2025) to 23.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 72.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 50.00 Cr..
- For Interest, as of Jun 2025, the value is 44.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 49.00 Cr. (Mar 2025) to 44.00 Cr., marking a decrease of 5.00 Cr..
- For Depreciation, as of Jun 2025, the value is 94.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 88.00 Cr. (Mar 2025) to 94.00 Cr., marking an increase of 6.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 211.00 Cr.. The value appears to be declining and may need further review. It has decreased from 330.00 Cr. (Mar 2025) to 211.00 Cr., marking a decrease of 119.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Mar 2025) to 25.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 158.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Mar 2025) to 158.00 Cr., marking a decrease of 94.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.93. The value appears to be declining and may need further review. It has decreased from 4.67 (Mar 2025) to 2.93, marking a decrease of 1.74.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:57 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,160 | 1,326 | 1,775 | 1,892 | 2,027 | 2,236 | 2,797 | 4,769 | 4,707 | 5,773 | 4,812 | 5,217 | 5,533 |
| Expenses | 951 | 1,121 | 1,402 | 1,478 | 1,618 | 1,884 | 2,226 | 3,258 | 3,421 | 4,292 | 4,062 | 4,273 | 4,422 |
| Operating Profit | 209 | 205 | 372 | 414 | 409 | 352 | 571 | 1,511 | 1,286 | 1,482 | 751 | 944 | 1,110 |
| OPM % | 18% | 15% | 21% | 22% | 20% | 16% | 20% | 32% | 27% | 26% | 16% | 18% | 20% |
| Other Income | 9 | 34 | 4 | 32 | 28 | 15 | 5 | 26 | 20 | 16 | 47 | 100 | 113 |
| Interest | 64 | 106 | 111 | 97 | 75 | 86 | 88 | 66 | 96 | 146 | 151 | 182 | 185 |
| Depreciation | 33 | 61 | 86 | 104 | 121 | 161 | 184 | 197 | 235 | 301 | 345 | 359 | 361 |
| Profit before tax | 121 | 72 | 180 | 245 | 241 | 121 | 304 | 1,275 | 975 | 1,051 | 301 | 504 | 676 |
| Tax % | 20% | -2% | 19% | 18% | 28% | 22% | 12% | 25% | 23% | 28% | 26% | 24% | |
| Net Profit | 97 | 74 | 145 | 200 | 173 | 95 | 267 | 956 | 750 | 760 | 224 | 380 | 510 |
| EPS in Rs | 12.64 | 9.47 | 18.36 | 3.78 | 3.27 | 1.78 | 5.00 | 17.82 | 13.96 | 14.12 | 4.15 | 7.05 | 9.45 |
| Dividend Payout % | 0% | 0% | 2% | 8% | 9% | 17% | 10% | 11% | 14% | 14% | 19% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -23.71% | 95.95% | 37.93% | -13.50% | -45.09% | 181.05% | 258.05% | -21.55% | 1.33% | -70.53% | 69.64% |
| Change in YoY Net Profit Growth (%) | 0.00% | 119.66% | -58.01% | -51.43% | -31.59% | 226.14% | 77.00% | -279.60% | 22.88% | -71.86% | 140.17% |
Laurus Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 3% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 5% |
| 3 Years: | -23% |
| TTM: | 113% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 16% |
| 1 Year: | 79% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 11% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 9:40 am
Balance Sheet
Last Updated: May 13, 2025, 3:12 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 16 | 16 | 106 | 106 | 106 | 107 | 107 | 107 | 108 | 108 | 108 |
| Reserves | 281 | 645 | 790 | 1,250 | 1,407 | 1,484 | 1,709 | 2,605 | 3,281 | 3,949 | 4,099 | 4,456 |
| Borrowings | 605 | 888 | 1,081 | 808 | 947 | 1,009 | 1,051 | 1,411 | 1,653 | 1,714 | 2,110 | 2,380 |
| Other Liabilities | 372 | 344 | 342 | 509 | 547 | 718 | 872 | 1,502 | 1,567 | 1,187 | 1,351 | 1,643 |
| Total Liabilities | 1,273 | 1,893 | 2,229 | 2,673 | 3,008 | 3,318 | 3,739 | 5,625 | 6,609 | 6,958 | 7,667 | 8,587 |
| Fixed Assets | 499 | 801 | 1,014 | 1,193 | 1,448 | 1,599 | 1,694 | 1,818 | 2,186 | 2,884 | 3,036 | 2,888 |
| CWIP | 116 | 107 | 70 | 143 | 163 | 107 | 67 | 324 | 755 | 357 | 156 | 336 |
| Investments | 0 | 19 | 26 | 51 | 52 | 58 | 58 | 319 | 362 | 384 | 635 | 740 |
| Other Assets | 658 | 966 | 1,119 | 1,286 | 1,345 | 1,554 | 1,920 | 3,164 | 3,306 | 3,333 | 3,841 | 4,623 |
| Total Assets | 1,273 | 1,893 | 2,229 | 2,673 | 3,008 | 3,318 | 3,739 | 5,625 | 6,609 | 6,958 | 7,667 | 8,587 |
Below is a detailed analysis of the balance sheet data for Laurus Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 108.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 108.00 Cr..
- For Reserves, as of Mar 2025, the value is 4,456.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,099.00 Cr. (Mar 2024) to 4,456.00 Cr., marking an increase of 357.00 Cr..
- For Borrowings, as of Mar 2025, the value is 2,380.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,110.00 Cr. (Mar 2024) to 2,380.00 Cr., marking an increase of 270.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 1,643.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,351.00 Cr. (Mar 2024) to 1,643.00 Cr., marking an increase of 292.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 8,587.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7,667.00 Cr. (Mar 2024) to 8,587.00 Cr., marking an increase of 920.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2,888.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,036.00 Cr. (Mar 2024) to 2,888.00 Cr., marking a decrease of 148.00 Cr..
- For CWIP, as of Mar 2025, the value is 336.00 Cr.. The value appears strong and on an upward trend. It has increased from 156.00 Cr. (Mar 2024) to 336.00 Cr., marking an increase of 180.00 Cr..
- For Investments, as of Mar 2025, the value is 740.00 Cr.. The value appears strong and on an upward trend. It has increased from 635.00 Cr. (Mar 2024) to 740.00 Cr., marking an increase of 105.00 Cr..
- For Other Assets, as of Mar 2025, the value is 4,623.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,841.00 Cr. (Mar 2024) to 4,623.00 Cr., marking an increase of 782.00 Cr..
- For Total Assets, as of Mar 2025, the value is 8,587.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,667.00 Cr. (Mar 2024) to 8,587.00 Cr., marking an increase of 920.00 Cr..
Notably, the Reserves (4,456.00 Cr.) exceed the Borrowings (2,380.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -396.00 | -683.00 | 371.00 | -394.00 | -538.00 | 351.00 | 570.00 | 0.00 | 0.00 | 0.00 | 749.00 | 942.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 78 | 91 | 108 | 100 | 112 | 102 | 98 | 98 | 94 | 124 | 142 |
| Inventory Days | 165 | 210 | 177 | 184 | 199 | 201 | 233 | 257 | 279 | 211 | 258 | 258 |
| Days Payable | 114 | 101 | 91 | 110 | 106 | 144 | 157 | 194 | 140 | 90 | 151 | 138 |
| Cash Conversion Cycle | 112 | 187 | 177 | 183 | 193 | 169 | 177 | 161 | 237 | 216 | 231 | 262 |
| Working Capital Days | -50 | -0 | 20 | 7 | -7 | 9 | 19 | 50 | 57 | 67 | 56 | 56 |
| ROCE % | 25% | 15% | 17% | 17% | 14% | 8% | 14% | 38% | 23% | 22% | 8% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Mirae Asset Midcap Fund | 4,110,034 | 1.26 | 148.68 | 4,110,034 | 2025-04-22 17:25:28 | 0% |
| Kotak Emerging Equity Fund - Regular Plan | 2,828,962 | 0.3 | 102.34 | 2,828,962 | 2025-04-22 17:25:28 | 0% |
| PGIM India Midcap Opportunities Fund | 2,530,000 | 1.01 | 91.52 | 2,530,000 | 2025-04-22 17:25:28 | 0% |
| Franklin India Prima Fund | 2,422,358 | 1.03 | 87.63 | 2,422,358 | 2025-04-22 15:56:56 | 0% |
| Sundaram Mid Cap Fund | 2,119,699 | 0.9 | 76.68 | 2,119,699 | 2025-04-22 15:56:56 | 0% |
| Sundaram Mid Cap Fund - Institutional Plan | 2,119,699 | 0.9 | 76.68 | 2,119,699 | 2025-04-22 15:56:56 | 0% |
| Bandhan Sterling Value Fund | 1,700,000 | 0.92 | 61.5 | 1,700,000 | 2025-04-22 17:25:28 | 0% |
| Bandhan ELSS Tax Saver Fund | 1,600,000 | 1.15 | 57.88 | 1,600,000 | 2025-04-22 15:56:56 | 0% |
| Axis Small Cap Fund | 1,589,977 | 0.35 | 57.52 | 1,589,977 | 2025-04-22 17:25:28 | 0% |
| Franklin India Equity Advantage Fund | 1,100,000 | 1.43 | 39.79 | 1,100,000 | 2025-04-22 15:56:56 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 6.65 | 2.98 | 14.69 | 15.42 | 18.36 |
| Diluted EPS (Rs.) | 6.64 | 2.97 | 14.64 | 15.42 | 18.28 |
| Cash EPS (Rs.) | 14.56 | 10.26 | 20.81 | 20.17 | 22.16 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 82.99 | 76.28 | 75.16 | 62.51 | 48.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 82.99 | 76.28 | 75.16 | 62.51 | 48.47 |
| Revenue From Operations / Share (Rs.) | 103.05 | 93.53 | 112.14 | 91.85 | 89.70 |
| PBDIT / Share (Rs.) | 20.69 | 14.91 | 29.67 | 26.72 | 29.34 |
| PBIT / Share (Rs.) | 12.71 | 7.78 | 23.65 | 22.04 | 25.52 |
| PBT / Share (Rs.) | 8.99 | 4.39 | 20.59 | 20.17 | 24.25 |
| Net Profit / Share (Rs.) | 6.58 | 3.12 | 14.79 | 15.49 | 18.33 |
| NP After MI And SOA / Share (Rs.) | 6.65 | 2.98 | 14.67 | 15.40 | 18.33 |
| PBDIT Margin (%) | 20.07 | 15.94 | 26.45 | 29.09 | 32.70 |
| PBIT Margin (%) | 12.33 | 8.31 | 21.09 | 23.99 | 28.44 |
| PBT Margin (%) | 8.71 | 4.68 | 18.35 | 21.95 | 27.03 |
| Net Profit Margin (%) | 6.38 | 3.33 | 13.18 | 16.86 | 20.43 |
| NP After MI And SOA Margin (%) | 6.45 | 3.18 | 13.08 | 16.76 | 20.43 |
| Return on Networth / Equity (%) | 8.01 | 3.90 | 19.56 | 24.69 | 37.86 |
| Return on Capital Employeed (%) | 11.82 | 7.94 | 24.37 | 27.63 | 41.57 |
| Return On Assets (%) | 3.83 | 1.91 | 10.31 | 11.87 | 17.10 |
| Long Term Debt / Equity (X) | 0.14 | 0.19 | 0.18 | 0.17 | 0.16 |
| Total Debt / Equity (X) | 0.60 | 0.60 | 0.48 | 0.51 | 0.50 |
| Asset Turnover Ratio (%) | 0.62 | 0.62 | 0.82 | 0.76 | 1.02 |
| Current Ratio (X) | 1.22 | 1.23 | 1.42 | 1.25 | 1.25 |
| Quick Ratio (X) | 0.67 | 0.63 | 0.73 | 0.59 | 0.61 |
| Inventory Turnover Ratio (X) | 1.28 | 1.37 | 1.51 | 1.40 | 1.95 |
| Dividend Payout Ratio (NP) (%) | 12.03 | 53.67 | 13.60 | 10.37 | 7.62 |
| Dividend Payout Ratio (CP) (%) | 5.47 | 15.80 | 9.64 | 7.95 | 6.31 |
| Earning Retention Ratio (%) | 87.97 | 46.33 | 86.40 | 89.63 | 92.38 |
| Cash Earning Retention Ratio (%) | 94.53 | 84.20 | 90.36 | 92.05 | 93.69 |
| Interest Coverage Ratio (X) | 5.55 | 4.39 | 9.68 | 14.26 | 23.10 |
| Interest Coverage Ratio (Post Tax) (X) | 2.76 | 1.92 | 5.82 | 9.27 | 15.43 |
| Enterprise Value (Cr.) | 35759.58 | 23483.39 | 17717.09 | 33370.29 | 20697.57 |
| EV / Net Operating Revenue (X) | 6.44 | 4.66 | 2.93 | 6.76 | 4.30 |
| EV / EBITDA (X) | 32.07 | 29.21 | 11.09 | 23.24 | 13.15 |
| MarketCap / Net Operating Revenue (X) | 5.96 | 4.19 | 2.61 | 6.42 | 4.04 |
| Retention Ratios (%) | 87.96 | 46.32 | 86.39 | 89.62 | 92.37 |
| Price / BV (X) | 7.40 | 5.14 | 3.91 | 9.46 | 7.48 |
| Price / Net Operating Revenue (X) | 5.96 | 4.19 | 2.61 | 6.42 | 4.04 |
| EarningsYield | 0.01 | 0.01 | 0.05 | 0.02 | 0.05 |
After reviewing the key financial ratios for Laurus Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.65. This value is within the healthy range. It has increased from 2.98 (Mar 24) to 6.65, marking an increase of 3.67.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.64. This value is within the healthy range. It has increased from 2.97 (Mar 24) to 6.64, marking an increase of 3.67.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.56. This value is within the healthy range. It has increased from 10.26 (Mar 24) to 14.56, marking an increase of 4.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 82.99. It has increased from 76.28 (Mar 24) to 82.99, marking an increase of 6.71.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 82.99. It has increased from 76.28 (Mar 24) to 82.99, marking an increase of 6.71.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 103.05. It has increased from 93.53 (Mar 24) to 103.05, marking an increase of 9.52.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.69. This value is within the healthy range. It has increased from 14.91 (Mar 24) to 20.69, marking an increase of 5.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.71. This value is within the healthy range. It has increased from 7.78 (Mar 24) to 12.71, marking an increase of 4.93.
- For PBT / Share (Rs.), as of Mar 25, the value is 8.99. This value is within the healthy range. It has increased from 4.39 (Mar 24) to 8.99, marking an increase of 4.60.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.58. This value is within the healthy range. It has increased from 3.12 (Mar 24) to 6.58, marking an increase of 3.46.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.65. This value is within the healthy range. It has increased from 2.98 (Mar 24) to 6.65, marking an increase of 3.67.
- For PBDIT Margin (%), as of Mar 25, the value is 20.07. This value is within the healthy range. It has increased from 15.94 (Mar 24) to 20.07, marking an increase of 4.13.
- For PBIT Margin (%), as of Mar 25, the value is 12.33. This value is within the healthy range. It has increased from 8.31 (Mar 24) to 12.33, marking an increase of 4.02.
- For PBT Margin (%), as of Mar 25, the value is 8.71. This value is below the healthy minimum of 10. It has increased from 4.68 (Mar 24) to 8.71, marking an increase of 4.03.
- For Net Profit Margin (%), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 3.33 (Mar 24) to 6.38, marking an increase of 3.05.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.45. This value is below the healthy minimum of 8. It has increased from 3.18 (Mar 24) to 6.45, marking an increase of 3.27.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.01. This value is below the healthy minimum of 15. It has increased from 3.90 (Mar 24) to 8.01, marking an increase of 4.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.82. This value is within the healthy range. It has increased from 7.94 (Mar 24) to 11.82, marking an increase of 3.88.
- For Return On Assets (%), as of Mar 25, the value is 3.83. This value is below the healthy minimum of 5. It has increased from 1.91 (Mar 24) to 3.83, marking an increase of 1.92.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 0.2. It has decreased from 0.19 (Mar 24) to 0.14, marking a decrease of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.60.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.62. There is no change compared to the previous period (Mar 24) which recorded 0.62.
- For Current Ratio (X), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 1.5. It has decreased from 1.23 (Mar 24) to 1.22, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has increased from 0.63 (Mar 24) to 0.67, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 4. It has decreased from 1.37 (Mar 24) to 1.28, marking a decrease of 0.09.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 12.03. This value is below the healthy minimum of 20. It has decreased from 53.67 (Mar 24) to 12.03, marking a decrease of 41.64.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.47. This value is below the healthy minimum of 20. It has decreased from 15.80 (Mar 24) to 5.47, marking a decrease of 10.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 87.97. This value exceeds the healthy maximum of 70. It has increased from 46.33 (Mar 24) to 87.97, marking an increase of 41.64.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.53. This value exceeds the healthy maximum of 70. It has increased from 84.20 (Mar 24) to 94.53, marking an increase of 10.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.55. This value is within the healthy range. It has increased from 4.39 (Mar 24) to 5.55, marking an increase of 1.16.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.76. This value is below the healthy minimum of 3. It has increased from 1.92 (Mar 24) to 2.76, marking an increase of 0.84.
- For Enterprise Value (Cr.), as of Mar 25, the value is 35,759.58. It has increased from 23,483.39 (Mar 24) to 35,759.58, marking an increase of 12,276.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.44. This value exceeds the healthy maximum of 3. It has increased from 4.66 (Mar 24) to 6.44, marking an increase of 1.78.
- For EV / EBITDA (X), as of Mar 25, the value is 32.07. This value exceeds the healthy maximum of 15. It has increased from 29.21 (Mar 24) to 32.07, marking an increase of 2.86.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 4.19 (Mar 24) to 5.96, marking an increase of 1.77.
- For Retention Ratios (%), as of Mar 25, the value is 87.96. This value exceeds the healthy maximum of 70. It has increased from 46.32 (Mar 24) to 87.96, marking an increase of 41.64.
- For Price / BV (X), as of Mar 25, the value is 7.40. This value exceeds the healthy maximum of 3. It has increased from 5.14 (Mar 24) to 7.40, marking an increase of 2.26.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 4.19 (Mar 24) to 5.96, marking an increase of 1.77.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Laurus Labs Ltd:
- Net Profit Margin: 6.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.82% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.01% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.76
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.67
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 74.3 (Industry average Stock P/E: 41.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.6
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Laurus Enclave, Plot Office 01, Edulapakabonangi Village, Vishakapatnam Andhra Pradesh 531021 | secretarial@lauruslabs.com https://www.lauruslabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Ravindranath Kancherla | Non Exe.Chairman&Ind.Director |
| Mr. V V Ravi Kumar | Executive Director & CFO |
| Dr. Satyanarayana Chava | Executive Director & CEO |
| Ms. Soumya Chava | Executive Director |
| Dr. C V Lakshmana Rao | Executive Director |
| Mr. Krishna Chaitanya Chava | Executive Director |
| Mrs. Aruna Rajendra Bhinge | Independent Director |
| Mr. Karnam Sekar | Independent Director |
| Dr. Rajesh Koshy Chandy | Independent Director |
| Mr. Ramesh Subrahmanian | Independent Director |
FAQ
What is the intrinsic value of Laurus Labs Ltd?
Laurus Labs Ltd's intrinsic value (as of 28 October 2025) is 420.21 which is 55.30% lower the current market price of 940.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 50,752 Cr. market cap, FY2025-2026 high/low of 956/473, reserves of ₹4,456 Cr, and liabilities of 8,587 Cr.
What is the Market Cap of Laurus Labs Ltd?
The Market Cap of Laurus Labs Ltd is 50,752 Cr..
What is the current Stock Price of Laurus Labs Ltd as on 28 October 2025?
The current stock price of Laurus Labs Ltd as on 28 October 2025 is 940.
What is the High / Low of Laurus Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Laurus Labs Ltd stocks is 956/473.
What is the Stock P/E of Laurus Labs Ltd?
The Stock P/E of Laurus Labs Ltd is 74.3.
What is the Book Value of Laurus Labs Ltd?
The Book Value of Laurus Labs Ltd is 91.1.
What is the Dividend Yield of Laurus Labs Ltd?
The Dividend Yield of Laurus Labs Ltd is 0.13 %.
What is the ROCE of Laurus Labs Ltd?
The ROCE of Laurus Labs Ltd is 9.47 %.
What is the ROE of Laurus Labs Ltd?
The ROE of Laurus Labs Ltd is 7.75 %.
What is the Face Value of Laurus Labs Ltd?
The Face Value of Laurus Labs Ltd is 2.00.